Ostarine, also called enobosarm or MK-2866, is the SARM most people meet first. It was designed to build muscle without the prostate and hair effects of testosterone, and it is sold online as a gentler alternative to steroids.
The published record is narrower than the marketing. In randomised trials lean mass rises by roughly 1 to 1.5 kg, and testosterone, SHBG and HDL cholesterol fall. This guide collects what is measured, what is assumed, and what to monitor, with links to the sources.
Key facts about Ostarine
| Chemical name | Enobosarm, also known as ostarine and MK-2866 |
| Class | Nonsteroidal selective androgen receptor modulator |
| Molecular formula | C19H14F3N3O3, molecular weight 389.3 |
| Approved status | Not approved anywhere, more than 25 years after the class began |
| Measured effect in trials | Lean body mass up roughly 1 to 1.5 kg, dose dependent |
| Measured costs in trials | Lower testosterone, SHBG and HDL cholesterol |
The first number is what trials measured in controlled settings, at controlled doses. It is not a promise for unsupervised use.
Source: Drug Testing and Analysis, 2026, PMID 42919612
What ostarine is and is not
Ostarine is a selective androgen receptor modulator. It binds the same androgen receptor that testosterone binds, but the promise was tissue selectivity: anabolic in muscle and bone, sparing in prostate and skin.
A 2026 review in Drug Testing and Analysis makes the important correction. Tissue selectivity is reproducible in animal models but is largely metabolic in origin and small in humans, and after more than 25 years no SARM has been approved for any indication. That sentence should sit at the top of every ostarine article and rarely does.
What randomised trials measured
The same 2026 review summarises the human data across SARMs: in randomised trials, lean body mass rises dose dependently by roughly 1 to 1.5 kg, while testosterone, sex hormone binding globulin and HDL cholesterol fall, with some compounds producing reversible rises in liver enzymes.
| What was measured | Direction | How to read it |
|---|---|---|
| Lean body mass | Up about 1 to 1.5 kg, dose dependent | A real but modest change, in the range of a few months of consistent training |
| Total testosterone | Down | Suppression is part of the class effect, not a rare reaction |
| SHBG | Down | Changes how much testosterone is free versus bound |
| HDL cholesterol | Down | The lipid signal that matters for long term cardiovascular risk |
| Liver enzymes | Reversible rises with some compounds | Reversible in trials does not mean harmless in unsupervised use |
What the trials did not measure is equally important: no large trial in healthy trained men at the doses sold online, and no long term safety data. Anyone quoting exact pounds gained from personal experience is quoting an anecdote.
Testosterone suppression and blood work
The idea that SARMs do not suppress testosterone is wrong, and the review above states the opposite plainly. Suppression appears in trials at therapeutic doses, which means it certainly appears at higher unsupervised doses.
| Marker | Why it matters | When to test |
|---|---|---|
| Total and free testosterone, morning | Shows how deep the suppression went | Baseline, week 4, after the course |
| LH and FSH | Tells whether the axis is turned down | Baseline, after the course |
| SHBG | Explains free testosterone changes | Baseline, end |
| Lipid panel | HDL falls on this class | Baseline, week 4, end |
| ALT, AST, bilirubin | Hepatotoxicity is documented in case reports | Baseline, week 4, end |
| Blood pressure | Cheap, daily, underrated | Daily |
If you need the recovery side in detail, our guide to post cycle therapy covers the timeline and the drug classes involved.
Liver and lipid signals
Two 2025 case reports in Cureus describe acute liver injury attributed to SARMs. One is a 40 year old man who presented with vague gastrointestinal symptoms after starting a SARM; the other reviews the mechanisms, including oxidative stress, altered lipid metabolism and direct hepatocellular toxicity.
Case reports do not tell you the rate of harm. They tell you the harm exists and is not always mild. Combined with the HDL drop seen in trials, this is the part of the ostarine profile that deserves the most caution, especially with alcohol, other hepatotoxic drugs, or pre existing liver disease.
Doses used and cycle length
There is no approved dose, so this is a description of what is used in practice, not a recommendation. Community protocols usually run 8 weeks, with 10 to 25 mg per day. Ostarine is sold alongside the other compounds in the SARM category, though trials in clinical populations used different schedules and different endpoints.
| Item | Typical practice | Reality check |
|---|---|---|
| Daily dose | 10 to 25 mg | Not derived from a dose ranging trial in healthy men |
| Course length | 8 weeks | Longer courses mean longer suppression and lipid exposure |
| Half-life | Roughly a day, so once daily dosing | Steady state is reached within about a week |
| Route | Oral liquid or capsules | Liquid products make dosing accuracy worse, not better |
Ostarine and women
A 2026 review in Life looked specifically at SARMs in women and concluded that the effects are not well defined, with far less evidence than in men and most data coming from preclinical work. Androgenic side effects are the practical concern: voice change, clitoral enlargement and facial hair are the markers that can outlast the course.
Legal status and product quality
Ostarine is not approved as a medicine anywhere. In the United States it is not a dietary supplement either: the FDA treats SARMs sold as supplements as unapproved drugs. In sport it is banned at all times by WADA.
Because ostarine is unapproved, quality depends entirely on the supplier. The checks that actually mean something are a verifiable batch code, a manufacturer that stands behind it, and an order that arrives with tracking and a matching product. Those are the things to ask for before price.
Recovery after stopping ostarine
Because ostarine suppresses the axis, the weeks after the last dose are part of the protocol, not an afterthought. The 2026 review is blunt about the mechanism: suppression of testosterone and sex hormone binding globulin appears in controlled trials at the doses studied, so an unsupervised eight week run at a higher dose does not produce a milder version of the same effect.
What recovery looks like in practice:
- the drug clears over days, but the axis does not restart on a timer
- morning total testosterone, LH and FSH are the markers that show whether it is restarting
- symptoms such as low libido, flat mood and poor recovery track the blood work, not the calendar
- if levels stay low for months, that is a medical question, not a supplement question
The broader picture of that phase, including the limited evidence behind post cycle therapy, is in our guide to post cycle therapy and in the Clomid for men article.
What to check before you order
Because ostarine is unapproved, the supplier is the only quality control that exists. A short checklist does more for you than any certificate image.
| Check | Why it matters | How to do it |
|---|---|---|
| Batch code on the pack | Links the product to a specific production run | Ask for the code before ordering, then verify it with the manufacturer |
| Sealed packaging | Opened or resealed packs are the weak point in any supply chain | Photograph the parcel before opening it |
| Dose and form | Capsules, tablets and liquids are dosed differently | Match the label to what you receive, then plan the dose from that |
| Tracking | Gives you proof of dispatch and a record if something goes wrong | Insist on it, keep the number until the parcel arrives |
| Storage | Heat and light degrade any compound | Dry, room temperature, away from sunlight |
The same logic applies to anything unapproved you buy online, from any supplier. There is no regulator standing between the order and the parcel, so the checks you do yourself are the ones that count.
Example structure, not a recommendation
The table below is a common shape for a run of this kind, written out so the timing and the checkpoints are visible. It is not advice, not a protocol to copy, and not a substitute for a doctor who has seen your blood work.
| Stage | What people typically do | What to check |
|---|---|---|
| Week 1 | 10 mg per day | Baseline blood work |
| Weeks 2 to 6 | 10 to 20 mg per day | Week 4 testosterone and liver enzymes |
| Week 8 | Stop at the planned date | Do not extend because results look good |
| After 4 weeks | Repeat axis panel | Total and free testosterone, LH, FSH |
Frequently Asked Questions
Where this fits on this site
SARMs sit in their own category, which you can browse at SARMs. If you are comparing classes rather than compounds, the existing guide to SARMs versus steroids covers the differences in law, side effects and results, and the article on what anabolic steroids are sets the baseline.
- PubChem compound summary for enobosarm, CID 11326715: molecular formula C19H14F3N3O3, molecular weight 389.3
- Selective Androgen Receptor Modulators in Sport: patterns of use, product contamination, health risks and doping control. Drug Testing and Analysis, 2026. PMID 42919612
- When Gains Go Wrong: a case of SARM related liver injury. Cureus, 2025. PMID 40765588
- Silent Threats to the Liver: acute hepatotoxicity attributed to SARMs. Cureus, 2025. PMID 40625511
- Selective Androgen Receptor Modulators in Women: what we know and what is still missing. Life, 2026. PMID 41752994
Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Ostarine is an unapproved drug, its long term safety is unknown, and blood work plus supervision are the minimum.